Bio-Rad launches vericheck ddPCR replication competent lentivirus and replication competent AAV kits for cell and gene therapy production

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the recent launch of the Vericheck ddPCR™ Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit.

The kits provide rapid, cost-effective solutions for the absolute quantification of replication-competent lentivirus (RCL) and replication-competent adeno-associated virus (RCAAV), supporting the safe and effective production of cell and gene therapies. 

Replication-competent viruses (RCVs) can infect cells and replicate to produce additional virions. RCVs can be generated through recombination events between the transfer plasmid and either the production plasmids or the packaging cell line's genome.

Fundamental to the safety of emerging cell and gene therapies, RCV testing of samples must be performed throughout the production process. 

Bio-Rad’s Vericheck ddPCR kits for detecting RCL and RCAAV provide a validated solution for highly specific and highly sensitive detection and quantification of viral replication genes, potentially indicating an RCV.

The tests are designed for Bio-Rad's QX Droplet Digital PCR (ddPCR) platforms, with a simple workflow including automated data analysis and flexible sample throughput. Compared to traditional cell culture–based methods for RCV testing, the kits significantly reduce cost and turnaround time, achieving results in as little as 8 hours. 

“As the number of cell and gene therapies entering the market increases, we see a growing emphasis on the need for products to ensure safety and efficacy across production processes. We believe that Droplet Digital PCR solutions can help address this unmet need,”

Carolyn Reifsnyder, Senior Director of Marketing at Bio-Rad

Carolyn adds, “The introduction of Bio-Rad’s newest Vericheck ddPCR kits for RCL and RCAAV to our growing portfolio reflects our ongoing commitment to providing innovative QC tools to support advances in the cell and gene therapy space.”  

To learn more about the Vericheck ddPCR kits for RCL and RCAAV detection, visit bio-rad.com/ddPCR-Vericheck-RCV

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bio-Rad Laboratories. (2024, March 13). Bio-Rad launches vericheck ddPCR replication competent lentivirus and replication competent AAV kits for cell and gene therapy production. News-Medical. Retrieved on April 14, 2024 from https://www.news-medical.net/news/20240227/Bio-Rad-launches-vericheck-ddPCR-replication-competent-lentivirus-and-replication-competent-AAV-kits-for-cell-and-gene-therapy-production.aspx.

  • MLA

    Bio-Rad Laboratories. "Bio-Rad launches vericheck ddPCR replication competent lentivirus and replication competent AAV kits for cell and gene therapy production". News-Medical. 14 April 2024. <https://www.news-medical.net/news/20240227/Bio-Rad-launches-vericheck-ddPCR-replication-competent-lentivirus-and-replication-competent-AAV-kits-for-cell-and-gene-therapy-production.aspx>.

  • Chicago

    Bio-Rad Laboratories. "Bio-Rad launches vericheck ddPCR replication competent lentivirus and replication competent AAV kits for cell and gene therapy production". News-Medical. https://www.news-medical.net/news/20240227/Bio-Rad-launches-vericheck-ddPCR-replication-competent-lentivirus-and-replication-competent-AAV-kits-for-cell-and-gene-therapy-production.aspx. (accessed April 14, 2024).

  • Harvard

    Bio-Rad Laboratories. 2024. Bio-Rad launches vericheck ddPCR replication competent lentivirus and replication competent AAV kits for cell and gene therapy production. News-Medical, viewed 14 April 2024, https://www.news-medical.net/news/20240227/Bio-Rad-launches-vericheck-ddPCR-replication-competent-lentivirus-and-replication-competent-AAV-kits-for-cell-and-gene-therapy-production.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Bio-Rad publishes new paper on generation, characterization of complex-specific antibodies